Evaluation of yield and viability of aDC1 polarizing dendritic cells used in an anti-HIV immunotherapy assay

• Grant number: 22/04994-0
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: May 01, 2022
• End date: December 31, 2022
• Field of knowledge: Biological Sciences - Immunology - Cellular Immunology
• Principal Investigator: Alberto José da Silva Duarte
• Grantee: Gabriela Oliveira Santos
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated research grant: 16/25212-9 - Therapeutic vaccine based on aDC1 dendritic cells pulsed with inactivated autologous virus for the control of viremia after ATI in HIV infected individuals, AP.TEM

Abstract

Dendritic cells-based immunotherapy requires the differentiation of these cells from precursor cells, monocytes. Monocytes constitute about 10% of the mononuclear cells present in peripheral blood, which represents a limited amount when considering the need for doses of immunotherapy in the order of about 1047 viable cells. In this sense, the monitoring of cell yield, as well as the determination of viability, after the entire process of differentiation of monocytes into DCs is an approach of great importance for planning and monitoring the quality of immunotherapy. (AU)